Evolution of right ventricular dysfunction and tricuspid regurgitation after TAVI: A prospective study.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
15 Apr 2022
Historique:
received: 02 07 2021
revised: 31 10 2021
accepted: 17 01 2022
pubmed: 23 1 2022
medline: 15 4 2022
entrez: 22 1 2022
Statut: ppublish

Résumé

Right ventricular (RV) dysfunction and tricuspid regurgitation (TR) may impact prognosis of patients undergoing Transcatheter Aortic Valve Implantation (TAVI). We aimed to evaluate the evolution of previous RV dysfunction and/or significant TR after TAVI procedure. All patients undergoing TAVI between January 2018 and January 2019 were enrolled in this prospective cohort. Patients with at least one right heart (RH) abnormality at baseline including RV dysfunction (TAPSE < 17 mm, S-wave < 9.5 cm/s, Fractional area change < 35%, Strain > -20%, Tei > 0.54) and/or significant TR (Effective Regurgitant Orifice Area ≥ 40 mm2 and/or Regurgitant Volume ≥ 45 mL) underwent transthoracic echocardiography at day 1 and 6-month after TAVI. The primary endpoint was the regression of pre-TAVI RV dysfunction and/or significant TR at 6-month follow-up. The study enrolled 144 patients including 76 women (52.8%) with a mean age of 81.1 ± 6.8 yo, a mean EuroSCORE 2 of 5.2 ± 3.9%. At least one RH abnormality was observed in 53 patients (36.8%). At 6-month, at least one RV dysfunction parameter significantly improved in 26 patients (63.4%), TAPSE increasing from 13.0 ± 2.6 to 16.0 ± 9.8 mm, p < 0.0001 and S-wave from 7.7 ± 1.2 to 10.0 ± 2.6 cm/s, p = 0.004. Among 31 patients with baseline significant TR, TR decreased in 14 (45.2%); p = 0.003. Among patients with baseline RH abnormalities, 13 (24.5%) fully recovered. Baseline significant TR was predictive of 6-month clinical outcomes (OR = 3.1, 95%CI = [1.01-9.0], p = 0.03). In our recent intermediate surgical risk TAVI population, RV dysfunction and/or significant TR are frequent at baseline and fully or partially recover in most patients at 6-month follow-up.

Sections du résumé

BACKGROUND BACKGROUND
Right ventricular (RV) dysfunction and tricuspid regurgitation (TR) may impact prognosis of patients undergoing Transcatheter Aortic Valve Implantation (TAVI). We aimed to evaluate the evolution of previous RV dysfunction and/or significant TR after TAVI procedure.
METHODS METHODS
All patients undergoing TAVI between January 2018 and January 2019 were enrolled in this prospective cohort. Patients with at least one right heart (RH) abnormality at baseline including RV dysfunction (TAPSE < 17 mm, S-wave < 9.5 cm/s, Fractional area change < 35%, Strain > -20%, Tei > 0.54) and/or significant TR (Effective Regurgitant Orifice Area ≥ 40 mm2 and/or Regurgitant Volume ≥ 45 mL) underwent transthoracic echocardiography at day 1 and 6-month after TAVI. The primary endpoint was the regression of pre-TAVI RV dysfunction and/or significant TR at 6-month follow-up.
RESULTS RESULTS
The study enrolled 144 patients including 76 women (52.8%) with a mean age of 81.1 ± 6.8 yo, a mean EuroSCORE 2 of 5.2 ± 3.9%. At least one RH abnormality was observed in 53 patients (36.8%). At 6-month, at least one RV dysfunction parameter significantly improved in 26 patients (63.4%), TAPSE increasing from 13.0 ± 2.6 to 16.0 ± 9.8 mm, p < 0.0001 and S-wave from 7.7 ± 1.2 to 10.0 ± 2.6 cm/s, p = 0.004. Among 31 patients with baseline significant TR, TR decreased in 14 (45.2%); p = 0.003. Among patients with baseline RH abnormalities, 13 (24.5%) fully recovered. Baseline significant TR was predictive of 6-month clinical outcomes (OR = 3.1, 95%CI = [1.01-9.0], p = 0.03).
CONCLUSION CONCLUSIONS
In our recent intermediate surgical risk TAVI population, RV dysfunction and/or significant TR are frequent at baseline and fully or partially recover in most patients at 6-month follow-up.

Identifiants

pubmed: 35065152
pii: S0167-5273(22)00123-1
doi: 10.1016/j.ijcard.2022.01.033
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-34

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Florence Leclercq (F)

Cardiology Department, Montpellier University Hospital, Montpellier University, France. Electronic address: f-leclercq@chu-montpellier.fr.

Laura Lorca (L)

Cardiology Department, Montpellier University Hospital, Montpellier University, France.

Audrey Agullo (A)

Cardiology Department, Montpellier University Hospital, Montpellier University, France.

Karim Bouchdoug (K)

Clinical Research and Epidemiology Unit, Medical Information Department, Montpellier University Hospital, Montpellier University, France.

Jean-Christophe Macia (JC)

Cardiology Department, Montpellier University Hospital, Montpellier University, France.

Delphine Delseny (D)

Cardiology Department, Montpellier University Hospital, Montpellier University, France.

François Roubille (F)

Cardiology Department, Montpellier University Hospital, Montpellier University, France; PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France.

Thomas Gandet (T)

Cardiovascular Surgery Department, Montpellier University Hospital, Montpellier University, France.

Benoit Lattuca (B)

Cardiology Department, Nîmes University Hospital, Montpellier University, France.

Pierre Robert (P)

Cardiology Department, Montpellier University Hospital, Montpellier University, France.

Laurent Schmutz (L)

Cardiology Department, Nîmes University Hospital, Montpellier University, France.

Guillaume Cayla (G)

Cardiology Department, Nîmes University Hospital, Montpellier University, France.

Claire Duflos (C)

Clinical Research and Epidemiology Unit, Medical Information Department, Montpellier University Hospital, Montpellier University, France.

Mariama Akodad (M)

Cardiology Department, Montpellier University Hospital, Montpellier University, France; Clinical Research and Epidemiology Unit, Medical Information Department, Montpellier University Hospital, Montpellier University, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH